Amyopathic Dermatomyositis — SCE Dermatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Clinically amyopathic dermatomyositis (CADM)
Clinically amyopathic dermatomyositis (CADM) presents with characteristic DM skin findings (heliotrope rash, Gottron papules, V-sign, shawl sign) but with minimal or absent clinical muscle involvement and normal or near-normal CK. Anti-MDA5 is the hallmark antibody associated with CADM. Crucially, anti-MDA5-positive CADM carries a high risk of rapidly progressive interstitial lung disease (RP-ILD), which can be fatal within months if not treated aggressively. Despite the absence of clinically significant myositis, these patients require urgent pulmonary assessment (HRCT, PFTs) and aggressive immunosuppression (triple therapy: corticosteroids + calcineurin inhibitor + cyclophosphamide) if ILD is detected.
Reference: BAD 2016 DM Guidelines; Rheumatology 2019